180
Participants
Start Date
January 31, 2023
Primary Completion Date
August 23, 2024
Study Completion Date
May 29, 2025
Deucravacitinib
Specified dose on specified days.
Placebo
Specified dose on specified days.
Local Institution - 0032, New York
Local Institution - 0013, New York
Local Institution - 0001, Rochester
Local Institution - 0024, Washington D.C.
Local Institution - 0018, Rockville
Local Institution - 0019, Charleston
Local Institution - 0020, Snellville
Local Institution - 0037, Atlanta
Riverchase Dermatology, Pembroke Pines
Local Institution - 0016, Coral Gables
Local Institution - 0027, Brandon
Local Institution - 0005, Bexley
Local Institution - 0012, Mayfield Heights
Local Institution - 0010, Auburn Hills
Local Institution - 0002, Waterford
Local Institution - 0007, Rolling Meadows
Local Institution - 0025, Skokie
Local Institution - 0036, Springfield
Local Institution - 0003, Baton Rouge
Local Institution - 0015, North Little Rock
Local Institution - 0028, Frisco
Local Institution - 0029, Cypress
Local Institution - 0030, Centennial
Local Institution - 0008, South Jordan
Local Institution - 0033, Springville
Local Institution - 0006, Phoenix
Local Institution - 0034, Scottsdale
Local Institution - 0017, Las Vegas
Local Institution - 0035, Reno
Local Institution - 0022, San Diego
Local Institution - 0004, Bakersfield
Local Institution - 0009, Sacramento
Local Institution - 0021, Bellevue
Local Institution - 0031, Mill Creek
Local Institution - 0014, Spokane
Local Institution - 0040, Caguas
Local Institution - 0038, Carolina
Local Institution - 0039, San Juan
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY